FAKTOR-OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 11:36:44 14/06/2024 BST | ||
| 55.27 EUR | +2.28% |
|
| Current month | +25.41% | ||
| 1 month | +35.13% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 55.27 | +2.28% |
| 13/06/24 | 54.04 | -5.04% |
| 12/06/24 | 56.91 | -1.16% |
| 11/06/24 | 57.58 | +0.70% |
| 10/06/24 | 57.18 | -2.07% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 11:36 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MD0HTL |
| ISIN | DE000MD0HTL2 |
| Date issued | 13/12/2021 |
| Strike | 319.4 $ |
| Maturity | Unlimited |
| Parity | 2.64 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 58.39 € |
|---|---|
| Lowest since issue | 9.81 € |
| Spread | 0.18 € |
| Spread % | 0.31% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
480.7
USD
Average target price
463.4
USD
Spread / Average Target
-3.60%
- Stock Market
- Certificates
- Certificat
